Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dosevial (US RLD -TRISENOX@). It will be manufactured at Alidac Pharmaceuticals Ltd., the company's wholly-owned subsidiary located at SEZ, Ahmedabad. Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.
The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.359.75 as compared to the previous close of Rs. 370.25. The total number of shares traded during the day was 56460 in over 935 trades.
The stock hit an intraday high of Rs. 371.45 and intraday low of 358.2. The net turnover during the day was Rs. 20491337.